To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
Not yet recruitingOBSERVATIONAL
Enrollment
100
Participants
Timeline
Start Date
March 20, 2024
Primary Completion Date
March 20, 2029
Study Completion Date
March 20, 2029
Conditions
Epithelial Ovarian CancerStage III Ovarian CancerStage IV Ovarian Cancer
All Listed Sponsors
lead
The First Hospital of Jilin University
OTHER
NCT06315270 - To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter